| Literature DB >> 35728864 |
Sander Dijkstra1, Maarten Otten1, Gréanne Leeftink2, Bas Kamphorst3, Angelique Olde Meierink4, Anouk Heinen5, Rhodé Bijlsma6, Richard J Boucherie1.
Abstract
BACKGROUND: Distancing measures enforced by the COVID-19 pandemic impose a restriction on the number of patients simultaneously present in hospital waiting areas.Entities:
Keywords: COVID-19; Decision support, computerised; Efficiency, Organizational; Outpatients; Simulation
Mesh:
Year: 2022 PMID: 35728864 PMCID: PMC9214409 DOI: 10.1136/bmjoq-2021-001703
Source DB: PubMed Journal: BMJ Open Qual ISSN: 2399-6641
Patient trajectories in Rheumatology Clinic of SMK and Medical Oncology & Haematology Outpatient Clinic of UMCU
| Trajectory | Stage 1 | Stage 2 | Stage 3 | Stage 4 | Digital consultation possible? | Bridging time before Stage 2 | Bridging time before Stage 3 | Bridging time before Stage 4 | Number of occurrences in blueprint | |
|
| ||||||||||
| A | New patient | No | – | – | – | 28 | ||||
| B | Follow-up 1 | Yes | – | – | – | 28 | ||||
| C | Follow-up 2 | Pharmacy | No | – | – | 15 | 26 | |||
| D | Follow-up 2 | Blood test | No | – | – | 15 | 34 | |||
| E | Follow-up 2 | Yes | – | – | – | 28 | ||||
| F | Blood test | Follow-up | Follow-up 2 | No | 0 | 30 | 15 | 12 | ||
| G | Blood test | Follow-up | Follow-up 2 | Pharmacy | No | 0 | 30 | 15 | 26 | |
| A-PA | New patient | No | – | – | – | 6 | ||||
| B-PA | Follow-up 1 | Yes | – | – | – | 6 | ||||
| C-PA | Follow-up 2 | Pharmacy | No | – | – | 15 | 12 | |||
| D-PA | Follow-up 2 | Blood test | No | – | – | 15 | 16 | |||
| E-PA | Follow-up 2 | Yes | – | – | – | 14 | ||||
| F-PA | Blood test | Follow-up | Follow-up 2 | No | 0 | 30 | – | 12 | ||
| G-PA | Blood test | Follow-up | Follow-up 2 | Pharmacy | No | 0 | 30 | 15 | 6 | |
| H | New patient | No | – | – | – | 6 | ||||
| I | Follow-up | Yes | – | – | – | 4 | ||||
|
| ||||||||||
| A | New patient | Yes | – | – | – | 10 | ||||
| B | Follow-up | Yes | – | – | – | 36 | ||||
| C | Blood test | Follow-up | No | 60 | – | – | 28 | |||
| D-60 | Blood test | Follow-up | Chemoth. 60 min | No | 60 | 60 | – | 4 | ||
| D-90 | Blood test | Follow-up | Chemoth. 90 min | No | 60 | 60 | – | 9 | ||
| D-120 | Blood test | Follow-up | Chemoth. 120 min | No | 60 | 60 | – | 12 | ||
| D-210 | Blood test | Follow-up | Chemoth. 210 min | No | 60 | 60 | 9 | |||
| E | New patient | Yes | – | – | – | 5 | ||||
| F | Follow-up | No | – | – | – | 21 | ||||
| G | Blood test | Follow-up | No | 60 | – | – | 44 | |||
| H-30 | Blood test | Follow-up | Chemoth. 30 min | No | 60 | 45 | – | 6 | ||
| H-60 | Blood test | Follow-up | Chemoth. 60 min | No | 60 | 45 | – | 4 | ||
| H-120 | Blood test | Follow-up | Chemoth. 120 min | No | 60 | 45 | – | 3 | ||
| H-180 | Blood test | Follow-up | Chemoth. 180 min | No | 60 | 45 | – | 1 | ||
| I-30 | Follow-up | Chemoth. 30 min | No | – | 45 | – | 2 | |||
| I-60 | Follow-up | Chemoth. 60 min | No | – | 45 | – | 1 | |||
| I-120 | Follow-up | Chemoth. 120 min | No | – | 45 | – | 1 | |||
| I-180 | Follow-up | Chemoth. 180 min | No | – | 45 | – | 1 | |||
| J-60 | Chemoth. 60 min | No | – | – | – | 2 | ||||
| J-90 | Chemoth. 90 min | No | – | – | – | 6 | ||||
| J-120 | Chemoth. 120 min | No | – | – | – | 7 | ||||
| J-210 | Chemoth. 210 min | No | – | – | – | 6 | ||||
| K-30 | Chemoth. 30 min | No | – | – | – | 5 | ||||
| K-60 | Chemoth. 60 min | No | – | – | – | 4 | ||||
| K-120 | Chemoth. 120 min | No | – | – | – | 2 | ||||
| K-180 | Chemoth. 180 min | No | – | – | – | 3 | ||||
For each trajectory, the appointment type per stage is denoted together with the option to replace a consultation with a digital consultation, the minimum bridging times (min) and the number of occurrences required in the blueprint schedule. For SMK, trajectories with identical Stage 3 appointment type have a similar colour tone. For UMCU, trajectories with identical Stage 2 appointment type have a similar colour tone.
SMK, Sint Maartenskliniek; UMCU, University Medical Center Utrecht.
Figure 1Waiting area occupancy outcomes of the worst-case and best-case realisations of the pre-COVID-19 blueprint schedule and the COVID-19 blueprint schedule resulting from our iterative approach for the Rheumatology Clinic in Sint Maartenskliniek.
Figure 2Waiting area occupancy outcomes of the worst-case and best-case realisations of the pre-COVID-19 blueprint schedule and the COVID-19 blueprint schedule resulting from our iterative approach for the Medical Oncology & Haematology Outpatient Clinic in University Medical Center Utrecht.